Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study

Nature Medicine published an author correction on June 16, 2026, regarding a Global Burden of Disease Study. The correction addresses data on the global burden of amphetamine, cannabis, cocaine, and opioid use across 204 countries from 1990 to 2023, according to the publication doi:10.1038/s41591-026-04513-4.

Why was the Global Burden of Disease Study corrected?

The publication serves as a formal author correction to a study tracking drug use burdens over a 33-year period. According to the record, the update ensures the accuracy of data involving amphetamine, cannabis, cocaine, and opioid use.

How does this correction affect health data?

Correcting these figures is necessary for maintaining the precision of long-term health trends. Because the study spans three decades, any adjustment to the data could alter the perceived trajectory of substance use burdens in the 204 included nations.

What may happen next?

Researchers who relied on the original figures may now update their own models. This correction could lead to a shift in how the burden of specific substances, such as opioids or cocaine, is interpreted in certain regions.

Future analyses of the 1990–2023 period are likely to use these revised numbers. This may result in updated reports from health organizations that utilize Global Burden of Disease data to allocate resources.

Frequently Asked Questions

Which substances were included in the study correction?

The correction applies to data regarding the use of amphetamine, cannabis, cocaine, and opioids.

How many countries were covered in the research?

According to the source, the study included 204 countries.

What was the timeframe of the data analyzed?

The data analyzed in the study spanned from 1990 to 2023.

How should global health organizations handle data updates in long-term epidemiological studies?